| 0.285 0.005 (1.79%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.37 | 1-year : | 0.43 |
| Resists | First : | 0.31 | Second : | 0.37 |
| Pivot price | 0.26  |
|||
| Supports | First : | 0.23 | Second : | 0.19 |
| MAs | MA(5) : | 0.26 |
MA(20) : | 0.27 |
| MA(100) : | 0.29 |
MA(250) : | 0.8 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 73.7 |
D(3) : | 49 |
| RSI | RSI(14): 52 |
|||
| 52-week | High : | 2.36 | Low : | 0.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MREO ] has closed below upper band by 17.6%. Bollinger Bands are 22.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.29 - 0.29 | 0.29 - 0.29 |
| Low: | 0.27 - 0.28 | 0.28 - 0.28 |
| Close: | 0.28 - 0.28 | 0.28 - 0.29 |
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
Fri, 04 Sep 2026
Mereo BioPharma Group PLC ADR (NASDAQ: MREO) Stock Price, News & Analysis - Kalkine
Mon, 17 Aug 2026
Here's Why We're Not Too Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Situation - simplywall.st
Tue, 11 Aug 2026
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights - Yahoo Finance
Sun, 26 Jul 2026
Mereo BioPharma Group plc Revenue Breakdown – NASDAQ:MREO - TradingView
Wed, 27 May 2026
MREO - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 160 (M) |
| Shares Float | 131 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 36 (%) |
| Shares Short | 4,320 (K) |
| Shares Short P.Month | 3,540 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.5 % |
| Return on Equity (ttm) | -67.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.01 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -1.43 |
| PEG Ratio | 0 |
| Price to Book value | 1.58 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|